-
Mashup Score: 0ASCO24
The 2024 ASCO Annual Meeting is the most significant gathering of oncology professionals worldwide, making connections and forging collaborations that can
Source: www.symplur.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3EHA24FEASIBILITY AND CLINICAL EFFICACY OF ATEZOLIZUMAB CONSOLIDATION IN... by Mr. Marcel Nijland - 6 hour(s) ago
EHA Library; Nijland M. Jun 13 2024; 422340;
Source: library.ehaweb.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1ASCO24Home - 8 hour(s) ago
Medscape is pleased to present several live symposia in Chicago, Illinois, in June 2024. These in-person and virtual events feature expert panelists who will guide interactive discussions and provide information on emerging topics, research, and treatment in Hematology-Oncology. There will be multiple opportunities for lively panel discussions and audience Q & A with the panelists. Join us in-person in Chicago for these exciting events. Learn more about each session below. Seats are limited, reserve
Source: events.medscapelive.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2ACC24
Reducing the levels of triglycerides and triglyceride-rich lipoproteins remains an unmet clinical need. Olezarsen is an antisense oligonucleotide targeting messenger RNA for apolipoprotein C-III (A…
Source: www.nejm.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 6ASCO24Contemporary Approach to Neurofibromatosis Type 1–Associated Malignant Peripheral Nerve Sheath Tumors - 11 hour(s) ago
Most malignant peripheral nerve sheath tumors (MPNSTs) are clinically aggressive high-grade sarcomas, arising in individuals with neurofibromatosis type 1 (NF1) at a significantly elevated estimated lifetime frequency of 8%-13%. In the setting of NF1, MPNSTs arise from malignant transformation of benign plexiform neurofibroma and borderline atypical neurofibromas. Composed of neoplastic cells from the Schwannian lineage, these cancers recur in approximately 50% of individuals, and most patients die within five years of diagnosis, despite surgical resection, radiation, and chemotherapy. Treatment for metastatic disease is limited to cytotoxic chemotherapy and investigational clinical trials. In this article, we review the pathophysiology of this aggressive cancer and current approaches to surveillance and treatment.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
Top Influencers of #ASCO24 👉 [5/2/24] @ASCO @ASCOPres @OncoAlert @PallOncCoP @FoxChaseCancer @DrN_CancerPCP @ramsedhom @eaonc @realbowtiedoc @efratdotan https://t.co/ujPNiaGRRh via @symplur TY @davisa20